Stocktoria

Cronos Group Inc. CRON

Nasdaq · stock · Medicinal Chemicals & Botanical Products · website · IPO 2014-05-07 · LEI

Cronos Group Inc. financials (annual)

Revenue
$13.2M $25.6M $54.4M $79.6M $109.3M $120.3M $161.8M $193.4M 20182019202020212022202320242025
Net income
-$21.6M $1.17B -$73.1M -$396.1M -$168.7M -$74.0M $41.1M -$9.4M 20182019202020212022202320242025
Free cash flow
-$95.8M -$169.9M -$176.3M -$164.8M -$92.4M -$45.3M $6.4M $149000 20182019202020212022202320242025

Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$193.4M$161.8M$120.3M$109.3M$79.6M$54.4M$25.6M$13.2M
Gross profit$62.8M$25.2M$11.9M$15.4M-$17.6M-$25.8M-$17.6M$6.2M
R&D expense$4.4M$4.2M$5.8M$13.1M$21.8M$20.4M$12.2M$1.8M
Operating income-$17.4M-$76.5M-$84.8M-$111.4M-$292.0M-$219.4M-$153.3M-$20.4M
Interest expense$13,000$27,000$186,000$1.2M$139,000
Income tax-$14.2M-$3.4M-$3.2M$34.2M-$431,000$1.3M$0$0
Net income-$9.4M$41.1M-$74.0M-$168.7M-$396.1M-$73.1M$1.2B-$21.6M
EPS (diluted)$-0.02$0.11$-0.19$-0.45$-1.07$-0.21$3.33$-0.12
Operating cash flow$25.9M$18.8M-$42.8M-$88.9M-$153.6M-$144.9M-$131.2M-$7.5M
Free cash flow$149,000$6.4M-$45.3M-$92.4M-$164.8M-$176.3M-$169.9M-$95.8M
Cash & equivalents$791.8M$858.8M$669.3M$764.6M$887.0M$1.1B$1.2B
Inventory$46.8M$33.1M$30.5M$37.6M$32.8M$44.0M$38.0M
Total assets$1.2B$1.2B$1.1B$1.2B$1.4B$1.9B$2.1B$183.5M
Total liabilities$54.2M$55.3M$44.1M$72.0M$63.5M$217.5M$341.4M
Shareholders' equity$1.1B$1.1B$1.1B$1.1B$1.3B$1.7B$1.7B$148.5M

Growth · year-over-year · Revenue CAGR 46.7%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue growth+19.5%+34.5%+10.0%+37.3%+46.5%+112.0%+93.7%
Net income growth-123.0%-106.3%
EPS growth-118.2%-106.3%
Free cash flow growth-97.7%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.